Mirati Therapeutics (MRTX) Announces Proposed $500M Share Offering

Mirati Therapeutics (MRTX) Prices 3.45M Share Offering at $145/sh

Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price to the public of $145.00 per share. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $500.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or about November 15, 2021, subject to customary closing conditions. Mirati has also granted the underwriters a 30-day option to purchase up to an additional 517,241... More

Mirati Therapeutics (MRTX) PT Raised to $235 at Stifel

Stifel analyst Ben Burnett raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $235.00 (from $202.00) while maintaining a Buy rating.

The analyst commented, "Were reiterating our Buy-rating following initial pembro+adagrasib frontline NSCLC data disclosed in conjunction with the company's 3Q21 update. The... More

Mirati Therapeutics (MRTX ) PT Raised to $175 at Morgan Stanley

Morgan Stanley analyst Michael Ulz raised the price target on Mirati Therapeutics (NASDAQ: MRTX ) to $175.00 (from $173.00) while maintaining a Equalweight rating.... More

Mirati Therapeutics (MRTX) Tops Q3 EPS by $1.24; Reports Cash and Cash Equivalents of $1.2B

Mirati Therapeutics (NASDAQ: MRTX) reported Q3 EPS of ($1.55), $1.34 better than the analyst estimate of ($2.89). Revenue for the quarter came in at $71.7 million versus the consensus estimate of $10.62 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.